Oslo, 3 May 2024: Reference is made to the stock exchange announcement published
on 30 April 2024 where Lytix Biopharma AS (the "Company") published a notice of
the Annual General Meeting to be held on 14 May 2024 at 13:00 (CEST) (the
"Notice").

In the Notice, the "Record Date" for shareholders who can attend and vote at the
Annual General Meeting was set to 9 May 2024. The correct "Record Date" is 6 May
2024.  

No other revisions have been made to the Notice or its appendices.

For further information, please see the Company's website or contact CFO Gjest
Breistein. Please see below for contact details.
Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com
Phone: +47 952 60 512 

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world leading research in host-defense
peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.